As the U.S. market navigates a period of retreat from record highs, with tech stocks experiencing notable declines, investors are closely monitoring key indices like the S&P 500 and Dow Jones Industrial Average for signs of broader economic trends. Amidst this backdrop, identifying high growth tech stocks requires a keen eye on companies that demonstrate resilience and adaptability in an evolving economic landscape.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
ACADIA Pharmaceuticals |
10.87% |
25.66% |
★★★★★☆ |
|
ADMA Biologics |
20.60% |
23.25% |
★★★★★☆ |
|
Palantir Technologies |
25.17% |
31.57% |
★★★★★★ |
|
Workday |
11.51% |
29.07% |
★★★★★☆ |
|
OS Therapies |
57.14% |
70.11% |
★★★★★☆ |
|
Circle Internet Group |
27.36% |
77.54% |
★★★★★☆ |
|
RenovoRx |
65.52% |
68.63% |
★★★★★☆ |
|
Gorilla Technology Group |
27.68% |
129.58% |
★★★★★☆ |
|
Vanda Pharmaceuticals |
22.66% |
59.11% |
★★★★★☆ |
|
Monopar Therapeutics |
76.01% |
54.38% |
★★★★★☆ |
Click here to see the full list of 71 stocks from our US High Growth Tech and AI Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MiMedx Group, Inc. is a company that develops and distributes placental tissue allografts for various sectors of healthcare, with a market cap of $1.05 billion.
Operations: MiMedx Group focuses on the development and distribution of placental tissue allografts, primarily serving the biotechnology sector with a revenue of $363.77 million.
MiMedx Group, despite recent challenges, shows promising signs of recovery and strategic growth. With a revised full-year revenue outlook increasing to low double digits, the company is outpacing the average US market growth forecast of 9.3%. This adjustment follows a robust Q2 performance with sales rising to $98.61 million from $87.21 million in the previous year. Additionally, MiMedx's earnings are set to surge by 24.6% annually, significantly ahead of the US market's 15.1%, reflecting strong underlying business dynamics despite a drop in net profit margin from 23.1% last year to 8.8%. The strategic alliance with Vaporox not only diversifies its wound care portfolio but also enhances its competitive edge by integrating advanced therapies like VHT with its products, potentially setting new standards in treatment efficacy and boosting future revenue streams.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MongoDB, Inc. provides a general-purpose database platform globally and has a market cap of approximately $25.68 billion.
